Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-P Baguet

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
Archives Des Maladies Du Coeur Et Des Vaisseaux|September 28, 1998
[The Hypertension Optimal Treatment Study: efficacy and tolerability on the 36th month]D Herpin, J M Mallion, A Benkritly, et al.
Revue Des Maladies Respiratoires|April 23, 2014
[Cardiovascular morbidity associated with obstructive sleep apnea syndrome]M Destors, R Tamisier, J-P Baguet, et al.
European Radiology|March 22, 2005
Renal artery entrapment by the diaphragmatic crusF Thony, J-P Baguet, M Rodiere, et al.
Vascular Health and Risk Management|May 14, 2009
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC studyJ P Baguet, R Asmar, P Valensi, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|September 28, 1998
[Models of arterial pressure using a Windkessel type model: role of the functional arterial properties]B Diourté, J P Siché, V Comparat, et al.
Computer Methods and Programs in Biomedicine|August 3, 1999
Study of arterial blood pressure by a Windkessel-type model: influence of arterial functional propertiesB Diourté, J P Siché, V Comparat, et al.
Presse Medicale (Paris, France : 1983)|December 9, 1995
[Ambulatory measurement of blood pressure]J M Mallion, F Tremel, J P Siché, et al.
La Revue De Medecine Interne|July 31, 2003
[Cardiovascular consequences of obstructive sleep apnea syndrome]J-P Baguet, J-L Pépin, L Hammer, et al.
International Journal of Clinical Practice|April 20, 2006
A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoringJ-P Baguet, S Nisse-Durgeat, S Mouret, et al.
Advances in Experimental Medicine and Biology|January 1, 1997
Left ventricular hypertrophy and arterial hypertrophyJ M Mallion, J P Baguet, J P Siché, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Archives Des Maladies Du Coeur Et Des Vaisseaux|September 28, 1998
[The Hypertension Optimal Treatment Study: efficacy and tolerability on the 36th month]D Herpin, J M Mallion, A Benkritly, et al.
Revue Des Maladies Respiratoires|April 23, 2014
[Cardiovascular morbidity associated with obstructive sleep apnea syndrome]M Destors, R Tamisier, J-P Baguet, et al.
European Radiology|March 22, 2005
Renal artery entrapment by the diaphragmatic crusF Thony, J-P Baguet, M Rodiere, et al.
Vascular Health and Risk Management|May 14, 2009
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC studyJ P Baguet, R Asmar, P Valensi, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|September 28, 1998
[Models of arterial pressure using a Windkessel type model: role of the functional arterial properties]B Diourté, J P Siché, V Comparat, et al.
Computer Methods and Programs in Biomedicine|August 3, 1999
Study of arterial blood pressure by a Windkessel-type model: influence of arterial functional propertiesB Diourté, J P Siché, V Comparat, et al.
Presse Medicale (Paris, France : 1983)|December 9, 1995
[Ambulatory measurement of blood pressure]J M Mallion, F Tremel, J P Siché, et al.
La Revue De Medecine Interne|July 31, 2003
[Cardiovascular consequences of obstructive sleep apnea syndrome]J-P Baguet, J-L Pépin, L Hammer, et al.
International Journal of Clinical Practice|April 20, 2006
A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoringJ-P Baguet, S Nisse-Durgeat, S Mouret, et al.
Advances in Experimental Medicine and Biology|January 1, 1997
Left ventricular hypertrophy and arterial hypertrophyJ M Mallion, J P Baguet, J P Siché, et al.
Pageof 7